Skip to content

H.R. 5850 · 118th Congress (2023–2025)

To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.

CRS summary not yet available.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 5850’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. Tracey Mann (R-KS-1)
Cosponsors
1 cosponsor

1 original · 0 later

  1. Rep. John R. Moolenaar (R-MI-2)· Original · Sep 29, 2023
Policy area
Health
Subjects
  • Abortion
  • Drug safety, medical device, and laboratory regulation
  • Prescription drugs

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 2 committee actions · Sep 29, 2023 – Oct 6, 2023
    1. Referred to committee

      Referred to the House Committee on Energy and Commerce.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred Sep 29, 2023
  2. HouseHealthReferred Oct 6, 2023

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (1)
  1. To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.

    Display title, Official title · Introduced in House